SCHEMBL6785277

SCHEMBL6785277

COc1cc(NC(=O)C=Cc2ccc3ccccc3c2)c(C(=O)O)cc1OC

nearest known ligand 0.78

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 3/20 0.78
MEN1 O00255 5/20 0.67
KMT2A Q03164 5/20 0.67
ALDH1A1 P00352 4/20 0.67
HPGD P15428 4/20 0.67
SMN1; SMN2 Q16637 4/20 0.67
NPC1 O15118 3/20 0.67
RAB9A P51151 3/20 0.67
NPSR1 Q6W5P4 3/20 0.67
TP53 P04637 2/20 0.67
CYP3A4 P08684 2/20 0.67
HIF1A Q16665 2/20 0.67
HSD17B10 Q99714 2/20 0.67
KDM4E B2RXH2 2/20 0.67
PKM P14618 2/20 0.67
CYP1A2 P05177 1/20 0.67
CYP2C9 P11712 1/20 0.67
CYP2C19 P33261 1/20 0.67
ABCC4 O15439 1/20 0.67
HPGDS O60760 1/20 0.67

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6785270 1.00 MAPT (0.78) MAPTMEN1KMT2AALDH1A1HPGD
SCHEMBL6784325 0.91 MAPT (0.64) MAPTMEN1KMT2AALDH1A1HPGD
SCHEMBL6784319 0.91 MAPT (0.64) MAPTMEN1KMT2AALDH1A1HPGD
SCHEMBL2844771 0.89 MEN1 (0.77) MAPTMEN1KMT2AALDH1A1HPGD
SCHEMBL2844767 0.89 MEN1 (0.77) MAPTMEN1KMT2AALDH1A1HPGD
SCHEMBL2839289 0.87 MAPT (0.79) MAPTMEN1KMT2AALDH1A1HPGD
SCHEMBL2839285 0.87 MAPT (0.79) MAPTMEN1KMT2AALDH1A1HPGD
SCHEMBL21024672 0.84 MAPT (0.74) MAPTMEN1KMT2AALDH1A1HPGD
SCHEMBL15396445 0.84 MAPT (0.74) MAPTMEN1KMT2AALDH1A1HPGD
SCHEMBL29966683 0.82 TRPM2 (0.69) MAPTMEN1KMT2AALDH1A1HPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6727250-B2 ADMINISTERING COMPOUNDS SUCH AS TRANS-3-(NAPHTH-2-YL)-BUT-2-ENOIC ACID-N-(2-CARBOXY-PHENYL)-AMIDE OR LIKE FOR THERAPY OF CONDITIONS ASSOCIATED WITH INCREASED TELOMERASE ACTIVITY, E.G. TUMOUR DISEASES BOEHRINGER INGELHEIM PHARMA KG (DE) 2004-04-27 US disclosed
US-20020099089-A1 Carboxylic acid amides, pharmaceutical compositions containing these compounds, their use and preparation BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) 2002-07-25 US disclosed
US-6362210-B1 ANTITUMOR, ANTICANCER AGENT BOEHRINGER INGELHEIM PHARMA KG (DE) 2002-03-26 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020099089-A1 Carboxylic acid amides, pharmaceutical compositions containing these compounds, their use and preparation TERT, NAT1, POT1 MAPT 1221/4885MEN1 896/4885KMT2A 490/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.